12 patients won't be enough to approve MPL for global use but it should be enough to gain the orphan drug designation.
If companies have less than 2 quarters of funding they just need to answer a few extra questions in their quarterly report. I've held a few companies that have done this without consequence.
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1375
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.020(8.89%) |
Mkt cap ! $96.99M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 24.5¢ | 22.5¢ | $150.8K | 649.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 50607 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
24.0¢ |
Change
0.020 ( 6.67 %) |
||||
| Open | High | Low | Volume | ||
| 22.5¢ | 24.0¢ | 22.5¢ | 231366 | ||
| Last updated 15.56pm 17/06/2024 ? | |||||
| PAA (ASX) Chart |
